Visual and Anatomic Outcomes From Ultracomplex Retinal Detachment Repair in a Large County Hospital.
| Autor: | Chen A; Northwest Permanente, Portland, OR., Coffee RE; Berkeley Eye Center, Houston, TX., Date RC; NJ Retina, Wayne, NJ., Weng CY; Department of Ophthalmology, Baylor College of Medicine-Cullen Eye Institute, Houston, TX.; Department of Ophthalmology, Ben Taub General Hospital, Houston, TX. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International ophthalmology clinics [Int Ophthalmol Clin] 2025 Jan 01; Vol. 65 (1), pp. 69-73. Date of Electronic Publication: 2024 Dec 23. |
| DOI: | 10.1097/IIO.0000000000000545 |
| Abstrakt: | Purpose: To evaluate outcomes of ultracomplex retinal detachment (UCRD) repairs performed at a large county hospital. Materials and Methods: Retrospective chart review of patients who underwent a UCRD repair, defined as a funnel retinal detachment (RD), RD associated with ocular trauma, or RD requiring retinectomy, 5000 centistoke silicone oil or perfluorocarbon heavy liquid (PFO). The outcomes examined were visual acuity (VA), anatomic success, and phthisis development. Results: Fifty eyes met inclusion criteria; 7 (14%) had a funnel RD, 14 (28%) had a history of ocular trauma, 34 (68%) had a retinectomy, 19 (38%) used 5000 centistoke silicone oil, and 12 (24%) used PFO. The mean follow-up time was 10.9±6.9 months. At 3 months, vision had remained stable or improved for 64% of eyes and the macula was attached for 66% of eyes. The mean preoperative VA was 2.5±0.5 logMAR, and the mean VA at 3 months was 2.4±0.7 logMAR with no statistically significant difference (P=0.30). With multivariate regression, preoperative VA was a statistically significant predictive factor of postoperative VA at 3 months. Nine (18%) of eyes developed phthisis, a mean of 11.4±5.1 months after UCRD repair. Conclusions: Surgical intervention for UCRD can stabilize vision and achieve anatomic success. Competing Interests: C.Y.W.: Allergan/AbbVie, Alcon, Apellis Pharmaceuticals, Alimera Sciences, DORC, Novartis, Genentech, Regeneron, REGENXBIO, Astellas/Iveric Bio, EyePoint (consultant); DRCR Retina Network, Alimera Sciences, AGTC (research); Springer Publishers (royalties). The remaining authors declare that they have no conflicts of interest to disclose. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|